The study was designed to determine whether the number of CD34 + /CD33 − cells given at autologous peripheral blood stem cell (PBSC) rescue after intensive therapy for cancer was a better predictor of platelet engraftment than the total number of CD34 + cells infused. + / CD33 + cells in the graft (r = 0.332). Engraftment times for platelets and neutrophils were evaluated in 68 patients. There was no significant difference between the times for platelets to reach Ͼ25 × 10 9 /l or neutrophils to reach Ͼ0.5 × 10 9 /l among patients who received Ͼ or Ͻ2 × 10 6 total CD34 + cells or Ͼ or Ͻ1.38 × 10 6 CD34 + /CD33 − cells although the latter was consistently the better predictor. Platelet recovery to Ͼ50 × 10 9 /l and Ͼ100 × 10 9 /l was delayed significantly in patients who received Ͻ1.38 × 10 6 CD34 + /CD33 − /kg infused (P Ͻ 0.02 and P Ͻ 0.05, respectively). The number of CD34 + / CD33 − cells/kg infused was a stronger predictor of platelet recovery than the total number of CD34 + cells infused (P Ͻ 0.05 for platelets Ͼ50 or Ͼ100 × 10 9 /l). Although platelet recovery was delayed significantly in patients who had Ͻ4 × 10 4 granulocyte-macrophage colony-forming units (CFU-GM)/kg infused, the time delay between receipt of PBSCs and availability of the colony counts limits the use of this assay to patients who do not require stem cells to be given immediately. Our data suggest that the number of CD34 + /CD33 − cells given at PBSC rescue provide information about the quality of the graft necessary for long-term platelet engraftment. However, since the percentage of CD34
mobilization or when a target dose of 2 × 10 6 total CD34
+ cells/kg is not achieved. Keywords: CD34 + /CD33 − ; platelet recovery; peripheral blood stem cells
There is increasing use of autologous peripheral blood stem cell (PBSC) rescue after intensive therapy for cancer. This is largely because patients recover granulocytes and platelets faster following PBSC than after autologous bone marrow (ABM) rescue, [1] [2] [3] and the harvesting procedure does not require a general anesthetic and can be done at outpatient clinics. In diseases where contamination with tumour cells could contribute to relapse, others suggest that the enhanced immune recovery after PBSC compared with ABM may contribute to the duration of remission by evoking an antitumour response. 4 Despite the success of PBSC, there is concern that some patients are slow to engraft for platelets, particularly after previous treatment with alkylating agents, [5] [6] [7] [8] [9] or radiotherapy, 7, 10 when the total yield of CD34 + progenitor cells may be low. Although fluorescence-activated cell analysis has enabled rapid quantitation of CD34 + cells in PBSC harvests, the heterogeneity of this population with respect to surface antigenic determinants suggests that estimates of the total number of CD34 + cells infused may not be the best indicator for long-term platelet engraftment. Most PBSC harvests contain CD34 + /CD33 + , as well as CD34 + /CD33 − cells, both of which can produce CFU-GM in vitro, 11, 12 but may not correlate equally with long-term platelet recovery. Furthermore, CD34/CD33 positivity is greater in mobilized PBSC from patients than from normal donors. 11 Although CFU-GM correlate with the total number of CD34 + cells 5, 6 they do not necessarily reflect the quality of PBSC with respect to platelet progenitors, since megakaryopoiesis is not assessed by this assay. Whilst CD34 + /CD33 + progenitor cells have enhanced capacity for GM-CFC formation in vitro, those which are CD34 + /CD33 − have an enriched capacity for the initiation of long-term culture. 13 This suggests that the contribution of CD34 + /CD33 − cells may be a better predictor of platelet engraftment than the total input of CD34 + cells since they are not committed necessarily to myelopoiesis. 12 Here, we have evaluated engraftment following PBSC 
Materials and methods

Patients
Between July 1995 and June 1997, 68 consecutive patients were enrolled for PBSC rescue. No selection was made on the basis of disease or previous treatment or whether mobilization occurred during first or second remission. All patients gave informed consent to take part in the study, following approval by the Ethics Committee at the Royal Marsden NHS Trust. Mobilization of progenitor cells was stimulated with granulocyte colony-stimulating factor (G-CSF; Amgen, Cambridge, UK) 12-16 g/kg/day on days 1-4 with harvest of stem cells on days 4 and 5. One patient who had three consecutive harvests was given a further dose of G-CSF on day 5. Patient characteristics are shown in Table 1 . Among five patients who had more than two collections, additional PBSC harvests were taken following remobilization after 2 weeks to 2 months from the first collections, when two aphereses were collected on consecutive days. PBSC were collected from patients by leukapheresis using a Cobe Spectra separator (Quidgeley, UK). No further processing was required. If the cells were to be reinfused the next day they were stored overnight at 4°C. For longer storage, cells were cryopreserved in liquid nitrogen, following programmed cooling to −140°C with 5% DMSO as cryopreservant. Neither the yield of CD34
+ cells nor that of CFU-GM are affected significantly by this procedure. Patients with NHL and Hodgkin's disease who received MBE were harvested in second or third remission, whereas those who had BEAM or Et/Mel were in first remission. Two of 29 patients with myeloma had received previous high-dose melphalan (HDM; Table 1 ). Clinical judgment for the amount of the total PBSC harvest given to patients was based on the yield of MNC. The protocol criteria were set so that patients received Ͼ2 × 10 8 and Ͻ5 × 10 8 MNC/kg. PBSC rescue was given 24 h after intensive therapy. Patients received antibiotic prophylaxis in accordance with protocols developed for individual units within the hospital. Antibiotics were started 5 days after PBSC and were changed if there was no response or the clinical situation demanded additional measures. Patients were considered to have engrafted and were discharged from hospital when platelets reached Ͼ25 × 10 9 /l and/or neutrophils were Ͼ0.5 × 10 9 /l. Long-term platelet recovery was considered to have been achieved when platelets were sustained at Ͼ100 × 10 9 /l on three separate occasions.
Flow cytometry
In most instances cells within each harvest were counted (Coulter Counter, Coulter, Luton, UK) and used for flow cytometric analysis within 2 h of collection. PBSCs were diluted 1:10 in phosphate-buffered saline (PBS 'A') and aliquots of 50 l were dispensed to tubes of ready conjugated antibody on a mixer and incubated at 4°C for 10 min. One millilitre of Ortho Lysis solution (Ortho Diagnostics, High Wycombe, UK) was added to lyse red cells and incubation continued at room temperature for 10 min. The tubes were transferred to an ice-bath and analysed for dual immuno-fluorescence immediately using a Cytoron Absolute (Ortho Diagnostics) with gating for mononuclear cells. The antibodies were mouse anti-human CD45-FITC/ CD14-PE and CD34-FITC/CD33-PE (Becton Dickinson, Cowley, UK). The machine was calibrated before use with normal donor blood which had been assessed for the differential count. Ten thousand events were accumulated for each sample. The data were collected in list mode file and analysed using the software supplied by the manufacturer. Subsequent calculations to estimate the yield of CD34
− cells in platelet engraftment BC Millar et al 471 cells were based on the total white cell count assayed by Coulter Counter.
CFU-GM
CFU-GM were assayed by methods described previously. 14 One hundred microlitres of conditioned medium from the bladder carcinoma cell line 5637 was used as a source of growth factors. Cells were plated in 35-mm plastic Petri dishes at 5 × 10 4 /dish in 1 ml of ␣ medium supplemented with 20% foetal calf serum and containing 0.3% agar (final concentration). Quadruplicate cultures were incubated for 14 days at 37°C in an atmosphere of 5% CO 2 /air and counted using an inverted microscope.
Statistical analysis
Comparison of the total number of CD34 + cells/kg infused with the number of CD34
+ /CD33 − cell/kg infused was made using least squares analysis. The time, in days, for patients to reach Ͼ0.5 × 10 9 /l neutrophils and Ͼ25, Ͼ50 and Ͼ100 × 10 9 /l platelets was recorded and comparisons made using the logrank test.
Results
Quality of PBSCs after mobilization with G-CSF
Twenty-four patients achieved Ͼ2 × 10 6 total CD34 
Analysis of neutrophil and platelet engraftment
Sixty-four of 68 patients recovered neutrophils to Ͼ0.5 × 10 Table 4 the median numbers of CD34 + /CD33 − , total CD34 + and CFU-GM at the same cut-off values are shown with the median values and range for recovery for neutrophils and platelets.
There was no significant difference in neutrophil recovery to Ͼ0.5 × 10 9 /l or platelet recovery to Ͼ25 × 10 9 /l between patients who received Ͼ or Ͻ2 × 10 6 total CD34 + cells/kg or Ͼ or Ͻ1.38 × 10 6 CD34 + /CD33 − cells/kg infused. Neutrophil recovery and platelet recovery to Ͼ25 × 10 9 /l was significantly shorter in patients who received Ͼ4 × 10 4 CFU-GM (P Ͻ 0.02 and P Ͻ 0.001, respectively).
Platelet recovery to Ͼ50 × 10 9 /l was increased significantly in patients who received Ͼ2 × 10 6 total CD34 + /kg or Ͼ1.38 × 10 6 /kg or Ͼ4 × 10 4 CFU-GM/kg (P Ͻ 0.05, P Ͻ 0.02 and P Ͻ 0.001, respectively). Platelet recovery to Ͼ100 × 10 9 /l did not reach significance in patients who received Ͼ2 × 10 6 total CD34 + cells/kg (P = 0.063) but was significant for patients who received Ͼ4 × 10 4 CFU-GM/kg 
/CD33
− cells/kg infused and the time to recover (a) platelets to Ͼ50 × 10 9 /l and (b) neutrophils to Ͼ0.5 × 10 9 /l. Figure 3 ).
Clinical outcome
There were no early deaths related to the transplant procedure. Seventeen patients did not recover platelets to Ͼ100 × 10 9 /l within 100 days of transplant, of whom three received Ͼ1.38 × 10 6 CD34 + /CD33 − cells/kg at PBSCR. Thirteen of these patients had progressive disease, of whom eight died. There were no deaths due to haemorrhage. Among relapsed patients three had multiple myeloma, seven non-Hodgkin's lymphoma, one Hodgkin's disease, one sarcoma and one gastro-intestinal cancer. Five of the 10 patients who had Ͻ1.38 × 10 6 CD34 + / CD33 − /kg infused and all three patients who had Ͼ1.38 × 10 6 cells/kg infused died. Two patients were lost to follow-up before platelets reached Ͼ100 × 10 9 /l. Two further patients have not recovered platelets to Ͼ100 × 10 9 /l more than 5 months after PBSC.
Discussion
Several authors have shown that transplantation with inadequate numbers of PBSC results in delayed platelet recovery. [5] [6] [7] [8] [9] [10] Although the progenitor cell population is heterogeneous, most studies have concentrated on the total dose of CD34 + cells as an indicator for engraftment. Transition from a primitive stem cell to functional cells of the haemopoietic system takes place through a number of intermediate stages characterized by the progressive loss of selfrenewal and increased lineage restriction, the acquisition of CD33 positivity being indicative of commitment to myelopoiesis. Our data provide evidence that long-term platelet recovery is more dependent on the number of CD34
− cells/kg infused than on the number of total CD34 + cells/kg; 2 × 10 6 total CD34 + cells/kg being predictive of 1.38 × 10 6 CD34 + /CD33 − cells. Since the number of CD34 + /CD33 − cells harvested from individual patients ranged from 0% to Ͼ90% of the total CD34
+ cells, mobilization of this more primitive population may be influenced by residual bone marrow reserve which may have been depleted due to age, disease type or previous treatment. Alternatively, the contribution of CD34 + /CD33 − cells to the total CD34 + population at harvest may reflect the kinetics of mobilization of different progenitor cell subsets in individual patients in response to G-CSF.
There was no significant difference between the times for platelet engraftment to Ͼ25 × 10 9 /l irrespective of the total dose of CD34 + or CD34 + /CD33 − cells. However, in patients who received either Ͻ2 × 10 6 total CD34 + cells/kg or Ͻ1.38 × 10 6 CD34 + /CD33 − cells/kg infused, recovery of platelets to Ͼ50 × 10 9 /l was delayed significantly. Furthermore, there was a stronger correlation between the number of CD34 + /CD33 − cells and platelet engraftment to this level than between the total number of CD34 + cells (Figure 3 , Tables 3 and 4) . Recovery of platelets to Ͼ100 × 10 9 /l was also determined better by the dose of CD34 + /CD33 − cells infused than by the total number of CD34 + cells. Although platelet recovery was delayed significantly in patients who received Ͻ4 × 10 4 CFU-GM/kg, the median day for platelet recovery at each quartile occurred later in patients who received greater or less than 4 × 10 4 CFU-GM/kg infused than in those who received greater or less than 1.38 × 10 6 /kg infused (Tables 3 and 4 ). The number of patients who received Ͼ4 × 10 4 CFU-GM/kg was 54, whereas only 19 received Ͼ1.38 × 10 6 CD34 + /CD33 − cells/kg suggesting that a higher target dose of CFU-GM should be set as an indicator of early engraftment. Thus, the dose of CD34 + /CD33 − cells was a better indicator of early platelet engraftment than that of CFU-GM. Furthermore, the 2-week interval required for colony formation renders this assay inappropriate for patients due for intensive therapy immediately after PBSC harvest.
During the study only 18 out of 68 patients received their total PBSC harvest, primarily because of concern that contaminating tumour cells may contribute to relapse and may be dependent on the total number of cells infused at PBSC rescue. [15] [16] [17] [18] Among the 13 patients who relapsed within 6 months of PBSC rescue only two had received their full PBSC harvest. Although the contribution of disease from the graft cannot be determined in these patients, evidence from other studies in NHL and multiple myeloma suggests that tumour cells within PBSC harvests have no effects on procedure-related deaths or engraftment. 19, 20 However, there is no evidence that unpurged PBSC harvests decrease the duration of response in these diseases.
Although G-CSF and GM-CSF have been given after ABM 21, 22 and PBSC rescue 23 to shorten the period of neutropenia there is no evidence that the time required for full platelet recovery is shortened. The isolation of thrombopoietin (TPO) [24] [25] [26] raised expectations that platelet recovery might be accelerated by its administration after rescue. However, in primates, whilst there was enhanced endogenous platelet recovery after 5 Gy in animals who received TPO, 27 there was no enhanced recovery in animals given autologous bone marrow after 8 Gy. 28 The authors suggested that there is a lack of appropriate precursors capable of responding to TPO immediately after rescue. Thus, timing of administration of TPO in humans may be critical to any therapeutic benefit.
In conclusion, CD34 + /CD33 − progenitor cells in PBSCs contributed to full platelet recovery (Ͼ100 × 10 9 /l) after intensive therapy and were a better predictor of recovery than the total dose of CD34 + cells. Because patient numbers for each of the pretransplant conditioning regimens were small, assessment of the role of any specific regimen on the rate of platelet recovery could not be made. Future studies will address this question and determine whether the release of CD34 + /CD33 − cells into the peripheral blood is affected by the conditions used for mobilization, age, disease and previous treatment. In the meantime, measurement of the CD34 + /CD33 − population is to be encouraged in situations where measurement of the total CD34 + population may give misleading values as to the quality of the PBSC harvest. For patients who have inadequate stem cell mobilization, attempts to expand CD34 + cells in vitro should aim to preserve this more primitive precursor so that the benefits of PBSC in early engraftment are not lost by the failure of platelet recovery to levels approaching those in normal donors. 
